DK0665844T3 - Substituerede benzylaminoquinuclidinforbindelser som antagonister af substans P - Google Patents
Substituerede benzylaminoquinuclidinforbindelser som antagonister af substans PInfo
- Publication number
- DK0665844T3 DK0665844T3 DK93922754T DK93922754T DK0665844T3 DK 0665844 T3 DK0665844 T3 DK 0665844T3 DK 93922754 T DK93922754 T DK 93922754T DK 93922754 T DK93922754 T DK 93922754T DK 0665844 T3 DK0665844 T3 DK 0665844T3
- Authority
- DK
- Denmark
- Prior art keywords
- carbon atoms
- alkyl
- hydrogen
- substituted
- compounds
- Prior art date
Links
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 title 1
- 102100024304 Protachykinin-1 Human genes 0.000 title 1
- 101800003906 Substance P Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- DTJXCCUWIKIZEX-UHFFFAOYSA-N n-benzyl-1-azabicyclo[2.2.2]octan-2-amine Chemical class C1C(CC2)CCN2C1NCC1=CC=CC=C1 DTJXCCUWIKIZEX-UHFFFAOYSA-N 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4283135A JP2656699B2 (ja) | 1992-10-21 | 1992-10-21 | 置換ベンジルアミノキヌクリジン |
PCT/US1993/009168 WO1994008997A1 (fr) | 1992-10-21 | 1993-09-30 | Benzylaminoquinuclidines substituees utilisees comme antagonistes de substance p |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0665844T3 true DK0665844T3 (da) | 2000-10-16 |
Family
ID=17661684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK93922754T DK0665844T3 (da) | 1992-10-21 | 1993-09-30 | Substituerede benzylaminoquinuclidinforbindelser som antagonister af substans P |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0665844B1 (fr) |
JP (1) | JP2656699B2 (fr) |
AT (1) | ATE196140T1 (fr) |
AU (1) | AU5165393A (fr) |
CA (1) | CA2146259C (fr) |
DE (1) | DE69329386T2 (fr) |
DK (1) | DK0665844T3 (fr) |
ES (1) | ES2149215T3 (fr) |
FI (1) | FI114636B (fr) |
GR (1) | GR3034498T3 (fr) |
HU (1) | HUT65133A (fr) |
IL (1) | IL107292A0 (fr) |
MX (1) | MX9306527A (fr) |
PT (1) | PT665844E (fr) |
WO (1) | WO1994008997A1 (fr) |
ZA (1) | ZA937780B (fr) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0790825A1 (fr) * | 1994-11-10 | 1997-08-27 | Pfizer Inc. | Antagonistes du recepteur nk-1 destines au traitement de troubles oculaires |
FR2728166A1 (fr) | 1994-12-19 | 1996-06-21 | Oreal | Composition topique contenant un antagoniste de substance p |
TW458774B (en) | 1995-10-20 | 2001-10-11 | Pfizer | Antiemetic pharmaceutical compositions |
FR2741262B1 (fr) | 1995-11-20 | 1999-03-05 | Oreal | Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene |
US6861526B2 (en) | 2002-10-16 | 2005-03-01 | Pfizer Inc. | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine |
KR101412339B1 (ko) | 2004-07-15 | 2014-06-25 | 알바니 몰레큘라 리써치, 인크. | 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를차단하기 위한 용도 |
US8362075B2 (en) | 2005-05-17 | 2013-01-29 | Merck Sharp & Dohme Corp. | Cyclohexyl sulphones for treatment of cancer |
CN101495184A (zh) | 2005-07-15 | 2009-07-29 | Amr科技公司 | 芳基和杂芳基取代的四氢苯并氮杂及其在阻断去甲肾上腺素多巴胺和血清素的重摄取中的应用 |
AU2006297443B2 (en) | 2005-09-29 | 2010-08-12 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
EP2083831B1 (fr) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
SI2805945T1 (sl) | 2007-01-10 | 2019-09-30 | Msd Italia S.R.L. | Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP) |
AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
CA2690191C (fr) | 2007-06-27 | 2015-07-28 | Merck Sharp & Dohme Corp. | Derives de 4-carboxybenzylamino utilises en tant qu'inhibiteurs de l'histone desacetylase |
CA2717509A1 (fr) | 2008-03-03 | 2009-09-11 | Tiger Pharmatech | Inhibiteurs de la tyrosine kinase |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
UA105182C2 (ru) | 2008-07-03 | 2014-04-25 | Ньюрексон, Інк. | Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность |
EP2413932A4 (fr) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | Inhibiteurs de l'activité akt |
CA2760837C (fr) | 2009-05-12 | 2018-04-03 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline et son utilisation |
US9034899B2 (en) | 2009-05-12 | 2015-05-19 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
US8815894B2 (en) | 2009-05-12 | 2014-08-26 | Bristol-Myers Squibb Company | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
CA2777043C (fr) | 2009-10-14 | 2015-12-15 | Schering Corporation | Piperidines substituees qui accroissent l'activite de p53, et utilisations de ces composes |
US8999957B2 (en) | 2010-06-24 | 2015-04-07 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as ERK inhibitors |
US8518907B2 (en) | 2010-08-02 | 2013-08-27 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) |
EP2606134B1 (fr) | 2010-08-17 | 2019-04-10 | Sirna Therapeutics, Inc. | Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani) |
US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
WO2012030685A2 (fr) | 2010-09-01 | 2012-03-08 | Schering Corporation | Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk |
WO2012036997A1 (fr) | 2010-09-16 | 2012-03-22 | Schering Corporation | Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk |
EP3766975A1 (fr) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina) |
US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
WO2012143879A1 (fr) | 2011-04-21 | 2012-10-26 | Piramal Healthcare Limited | Forme cristalline d'un sel d'un dérivé de morpholinosulfonylindole et son procédé de préparation |
EP2770987B1 (fr) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Nouveaux composés qui sont des inhibiteurs d'erk |
WO2013165816A2 (fr) | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | Compositions de petit acide nucléique interférent (sina) |
AU2013323508B2 (en) | 2012-09-28 | 2017-11-02 | Merck Sharp & Dohme Corp. | Novel compounds that are ERK inhibitors |
ES2651347T3 (es) | 2012-11-28 | 2018-01-25 | Merck Sharp & Dohme Corp. | Composiciones y métodos para el tratamiento del cáncer |
CA2895504A1 (fr) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Imidazopyridines substituees en tant qu'inhibiteurs de hdm2 |
US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
EP3525785A4 (fr) | 2016-10-12 | 2020-03-25 | Merck Sharp & Dohme Corp. | Inhibiteurs de kdm5 |
WO2019094311A1 (fr) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
EP3833667B1 (fr) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Inhibiteurs de prmt5 |
WO2020033282A1 (fr) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990005525A1 (fr) * | 1988-11-23 | 1990-05-31 | Pfizer Inc. | Derives de quinuclidine en tant qu'antagonsites de substance p |
RU2092486C1 (ru) * | 1991-05-22 | 1997-10-10 | Пфайзер Инк. | Замещенные 3-аминохинуклидины |
-
1992
- 1992-10-21 JP JP4283135A patent/JP2656699B2/ja not_active Expired - Fee Related
-
1993
- 1993-09-30 AU AU51653/93A patent/AU5165393A/en not_active Abandoned
- 1993-09-30 AT AT93922754T patent/ATE196140T1/de not_active IP Right Cessation
- 1993-09-30 ES ES93922754T patent/ES2149215T3/es not_active Expired - Lifetime
- 1993-09-30 CA CA002146259A patent/CA2146259C/fr not_active Expired - Fee Related
- 1993-09-30 WO PCT/US1993/009168 patent/WO1994008997A1/fr active IP Right Grant
- 1993-09-30 DE DE69329386T patent/DE69329386T2/de not_active Expired - Fee Related
- 1993-09-30 PT PT93922754T patent/PT665844E/pt unknown
- 1993-09-30 EP EP93922754A patent/EP0665844B1/fr not_active Expired - Lifetime
- 1993-09-30 DK DK93922754T patent/DK0665844T3/da active
- 1993-10-14 IL IL107292A patent/IL107292A0/xx not_active IP Right Cessation
- 1993-10-20 MX MX9306527A patent/MX9306527A/es unknown
- 1993-10-20 HU HU9302965A patent/HUT65133A/hu unknown
- 1993-10-20 ZA ZA937780A patent/ZA937780B/xx unknown
- 1993-10-20 FI FI934626A patent/FI114636B/fi active IP Right Grant
-
2000
- 2000-09-28 GR GR20000402187T patent/GR3034498T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
MX9306527A (es) | 1994-07-29 |
PT665844E (pt) | 2001-01-31 |
JP2656699B2 (ja) | 1997-09-24 |
GR3034498T3 (en) | 2000-12-29 |
IL107292A0 (en) | 1994-01-25 |
JPH06135963A (ja) | 1994-05-17 |
HU9302965D0 (en) | 1993-12-28 |
EP0665844B1 (fr) | 2000-09-06 |
CA2146259C (fr) | 1998-04-07 |
CA2146259A1 (fr) | 1994-04-28 |
WO1994008997A1 (fr) | 1994-04-28 |
ZA937780B (en) | 1995-04-20 |
ES2149215T3 (es) | 2000-11-01 |
AU5165393A (en) | 1994-05-09 |
FI934626A0 (fi) | 1993-10-20 |
DE69329386D1 (de) | 2000-10-12 |
HUT65133A (en) | 1994-04-28 |
FI934626A (fi) | 1994-04-22 |
DE69329386T2 (de) | 2001-01-04 |
EP0665844A1 (fr) | 1995-08-09 |
FI114636B (fi) | 2004-11-30 |
ATE196140T1 (de) | 2000-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0665844T3 (da) | Substituerede benzylaminoquinuclidinforbindelser som antagonister af substans P | |
ES534624A0 (es) | Un procedimiento para preparar un derivado de 1,8-naftiridina | |
MY109737A (en) | Treatment and compounds. | |
DK0447285T3 (da) | Nephtalenderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler indeholdende dem | |
DK0641328T3 (da) | Broforbundne, azabicykliske derivater som substans P-antagonister | |
CS89587A2 (en) | Zpusob vyroby arylcyklobutylalkylaminu | |
ES2098023T3 (es) | Compuestos de estructura guanidinica y composiciones farmaceuticas que los contienen. | |
EP0567090A3 (fr) | ||
KR970706280A (ko) | 5-HT1A 길항제로서의 비사이클릭 카복스아미드(Bicyclic carboxamides as 5-HT1 antagonists) | |
EP0626369A4 (fr) | Derive de benzenesulfonamide. | |
SE7502243L (fr) | ||
IS5623A (is) | Ný efnasambönd | |
ES2023760A6 (es) | Procedimiento para la preparacion de derivados benzotiazinicos. | |
ATE150030T1 (de) | Ureidoacetamid-derivate,irhe herstellung und sie enthaltende medikamente |